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Abstract  
Background  
Evidence of protection from childhood BCG against tuberculosis (TB) in adulthood, when 
most transmission occurs, is important for TB control and resource allocation. 
Methods  
We conducted a population-based case-control study of protection by  BCG given to children 
aged 12 to 13 years against tuberculosis occurring 10 to 29 years later.   We recruited UK-
born white subjects with tuberculosis and randomly sampled white community controls. 
Hazard ratios and 95% confidence intervals were estimated using case-cohort Cox 
regression, adjusting for potential confounding factors, including socio-economic status, 
smoking, drug use, prison and homelessness.  Vaccine effectiveness (VE=1-hazard ratio) 
was assessed at successive intervals more than 10 years following vaccination 
Results 
We obtained 677 cases and 1170 controls after a 65% response rate in both groups.  
Confounding by deprivation, education and lifestyle factors was slight 10-20 years after 
vaccination, more evident after 20 years.  VE 10 -15 years after vaccination was 51% (95% 
CI 21, 69%) and 57% (CI 33, 72%) at 15-20 years. Subsequently BCG protection appeared 
to wane; 20-25 years VE=25% (CI -14%, 51%) and 25-29 years VE= 1% (CI -84%, 47%). 
Based on multiple imputation of missing data (in 17% subjects) VE estimated in the same 
intervals after vaccination were similar (56% (CI 33, 72%), 57% (CI 36, 71%), 25% (-10, 
48%), 21% (-39, 55%).    
Conclusions 
School-age BCG vaccination offered moderate protection against tuberculosis for at least 20 
years which is longer than previously thought. This has implications for assessing the cost-
effectiveness of BCG vaccination and when evaluating new TB vaccines.   
(250 words) 
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Key words: BCG Vaccine, Bacillus Calmette-Guerin, Effectiveness, Duration, tuberculosis, 
epidemiology, prevention & control, England  
 
Key messages  
• It is unclear if protection by school age BCG vaccination against TB  continues in 
adulthood when most transmission occurs  
• Using a case-control study design based on 677 cases and 1170 controls we found 
about 50% protection that lasted 20 years and then waned  
• That BCG attributable protection against tuberculosis lasts longer than previously 
thought affects its cost-effectiveness and has implications for the evaluation of new 
TB vaccines.   
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Background 
Tuberculosis (TB) is a major, and potentially preventable, cause of morbidity and mortality 
globally with two to three billion of the world’s population infected with Mycobacterium 
tuberculosis,1 10% of whom progress to clinical disease.2 In 2015, 10.4 million people were 
estimated to have developed TB.1 TB incidence increases sharply in young adults3 and most 
cases of pulmonary disease, the main source of onward transmission, occur in adults. 
Progress in developing new TB vaccines is slow and BCG is the only licensed TB vaccine.4 . 
The efficacy of BCG in preventing TB varies geographically, particularly for pulmonary TB, 
with limited evidence of protection in many tropical areas.5, 6 Recent evidence suggest that 
BCG may act in part by protecting against infection.7  A large UK trial in the 1950s showed 
good protection against  TB for upto 15 years following BCG vaccination of secondary 
school-children,8 confirmed in observational studies to last at least 10 years after 
introduction into the UK national programme.9 Although there are few data on  protection, 
more than 10 years after vaccination,10, 11 studies in Brazil,12 in US Native-American 
populations13 and, more recently, in the Norwegian general population14 suggest BCG 
protection against TB can last longer. We aimed to provide confirmatory evidence of its 
durability in a case-control study of school-age BCG vaccination more than 10 years after 
vaccination in England. From the 1950s, BCG (based on the Danish strain15, 16) was offered 
routinely to schoolchildren in the UK aged about 13 years, until the programme was 
discontinued in 2005. 
 
Methods  
From 2102 to 2014 cases and controls were invited to take part in face-to-face interviews 
and to be examined for a BCG scar. We assessed protection from BCG vaccination 
administered to children 10 to 30 years previously, in five-year intervals after vaccination and 
tested for trends over time by analysing time since vaccination on a continuous scale.  
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Details of the study design are presented elsewhere17. In summary the study was restricted 
to persons of white ethnic group born in the UK. Other ethnic groups with a higher risk of TB 
were offered BCG in infancy. Cases were subjects living in England at diagnosis of a first TB 
episode notified between 2003 and 2012 to the Enhanced Tuberculosis Surveillance System 
(ETS) of Public Health England (PHE). Cases not known to be infected with HIV were 
included if they were between 23 and 38 years old at diagnosis (i.e. born between 1965 and 
1989, and aged 13 years between 1978 and 2002). Controls were UK-born subjects of white 
ethnic group without a previous history of tuberculosis, residing in England, selected from 
the general population and frequency-matched to cases by birth cohort (in 5-year bands). 
For logistic efficiency, recruitment of population-based controls was based on three-stage, 
self-weighted, cluster sampling across England17.   
  
Experienced field interviewers carried out Computer-assisted Personal Interviews (CAPI), 
following training specific to the study including inspecting both arms of all subjects to 
identify BCG vaccination scars. The training included scar reading of volunteers with and 
without scars and examination of photographs. Formal supervisory field visits and blind 
telephone recall interviews of at least 10% of study participants (selected at random) were 
conducted for quality control.   
 
No central databases of school vaccination records exist in the UK and records were not 
kept consistently in local child-health information systems. The classification of BCG 
vaccination status was based on a combination of participants self-reported history of BCG 
status (convincing history, probable history, no history) and scar inspection (present, not 
present, not examined).  As BCG was a vaccine given in school at about 12-13 years and 
usually caused a pustule and then a scar, recall by cases and controls was considered likely 
to be good. However several had difficulties recalling whether or not they had had a 
tuberculin skin test (TST) (children were only eligible for BCG vaccination if they were 
considered TST negative). These subjects were not excluded from the analysis. Instead, we 
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reviewed the impact of the likely proportion of unvaccinated participants who would have had 
a positive TST. 
 
Information on potential confounding factors, including demographic and social variables, 
was collected and compared in cases and controls. A measure of deprivation at the small 
area level (average 1,500 households) was obtained from Census data based on quintiles of 
the index of multiple deprivation (IMD) score in 2010.18 Education was assessed as highest 
education attainment and household crowding was calculated from current number of people 
in the household, number of rooms and bedrooms. Ever or never been in prison in the UK or 
elsewhere was noted, as was a history of being homeless for a week or more, and regular 
travel (defined as every few years or more often) and long stays (3 months or more) in high 
TB burden regions. Smoking was categorised as never, ex- or current, under or over 20 
pack-years. Alcohol consumption was based on frequency as well as quantity of UK 
standard units and recreational drug use as only non-Class A drugs (e.g. cannabis or 
solvents) or also using class A drugs (e.g. cocaine and heroin). Information on smoking, 
alcohol, drug use, prison and homelessness was collected using a Computer-Assisted self-
interview (CASI): interviewees entered the data on a laptop and then locked them to be 
inaccessible to the interviewer before returning the laptop.  
 
Ethics and consent 
The study was approved by the UK’s NHS National Research Ethics Service Committee. We 
obtained signed informed consent from those willing to take part.  Participants, irrespective 
of whether they completed the study or not, were given a £15 gift voucher as compensation 
for their time.  
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Statistical methods  
Cases and controls were compared across quintiles of the IMD score. We cross-tabulated 
history of BCG receipt and presence and absence of a BCG scar, assessing agreement 
using Cohen’s kappa coefficient. 
 
Hazard ratios (HR) for the association between BCG vaccination status and TB incidence 
were estimated using the case-cohort approach, with controls forming the sub-cohort.19, 20 
Controls were considered representative samples from the underlying population, as they 
were sampled at random from the underlying population within which cases arose 
(frequency matched by birth cohort in 5 year bands). TB rates are very low in the underlying 
population. The above approach allowed efficient use of data on the controls at different 
ages over time, as well as flexible modelling of vaccine effectiveness by time since 
vaccination.21 Vaccine effectiveness (VE) was defined as VE=1- HR. 
 
Based on a Cox regression model allowing a time-varying association between vaccination 
status and case-control status, each case was compared at its event time with all controls in 
the sub-cohort who were still at risk at that time (i.e. were interviewed at an age older than 
that of the case) and in the same year of birth stratum as the case. The time scale in these 
analyses was age, and vaccination status was a time-dependent variable. Self-reported age 
at vaccination, if available, was used to define vaccination status at a given age, otherwise 
the median age of 12 years in those reporting age at vaccination was assumed. The event 
time for cases was age at TB diagnosis, and the time of right censoring in controls was the 
age at interview for the study. Event times among cases were left-truncated on the day 
before the TB diagnosis date. Model parameters were estimated using a pseudo-partial 
likelihood analysis with robust standard errors as is required in a case-cohort analysis in 
which control groups are shared between cases19, 20. . 
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HRs were estimated within successive time-since-vaccination intervals, respectively 10-15, 
15-20, 20-25 and 25- 30 years after vaccination. Log HRs were also modelled as a smooth 
function of time-since-vaccination. Flexible models based on restricted cubic splines were 
compared, using the Akaike information criterion (AIC),22 with a model in which the log HR 
for BCG vaccination was assumed to change linearly with time-since-vaccination. 
 
All Cox models used separate baseline hazards by year of birth, to take into account the 
frequency-matching of controls by birth cohort. The baseline model was also adjusted for 
sex. Deprivation level and educational level were considered to be potentially important 
confounders and were added to the baseline model for separate analyses (partially adjusted 
model). In addition, other potential confounders were added in a further fully adjusted model, 
in which potential confounding variables were added one by one, and those judged to be 
important (i.e. changing the estimated log HR for BCG vaccination by +/-0.25 of the standard 
error of the log HR) were retained. Variables relating to lifestyle (smoking status, drinking 
behaviour, drug use) were included as a block in this procedure.  Any remaining variables 
were then added again one by one to the model and assessed for retention as before.  
  
Analyses were conducted first for those who had complete data on the variables included in 
the final model. In sensitivity analyses we fitted the baseline and partially adjusted models on 
all individuals with complete data for the model in question. Analyses were repeated using 
multiple imputation by chained equations to deal with missing data, under a ‘missing at 
random’ (MAR) assumption.23 (see details in Supplementary Methods available as 
supplementary data at IJE online).  
 
Results 
Of 1602 potentially eligible cases, 1047 (65%) were contacted successfully. Of these, 60 
were ineligible (not born in the UK or not white) and 53 had difficulties precluding 
participation such as frailty. Of the remaining 934, 257 (28%) refused and 677 (72%) were 
Page 9 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
10 
 
enrolled17   Of those enrolled 534 (80%) had pulmonary disease, 85% bacteriologically 
confirmed, the rest had extra-pulmonary disease of which 53% were laboratory confirmed.  
 
We recruited controls by sampling 9424 residential addresses.  For 13% the address no 
longer existed or no-one was at the address after repeated visits on different days and times. 
Among 8176 screened addresses 1790 (22%) had at least one eligible resident. We 
recruited from these addresses 1170 controls, a 65% response rate17. 
 
The distribution of visits by time of day and by day of week was similar in cases and 
controls17.  The proportions of contactable cases was slightly lower for those living in more 
deprived areas based on IMD quintiles. The proportion of addresses successfully screened 
to identify eligible controls was similar across IMD quintiles. (see Supplementary Table 1, 
available as supplementary data at IJE online). Among eligible cases contacted, the refusal 
rate was slightly higher for those living in the least deprived quintiles. The proportion of 
addresses successfully screened to identify eligible controls was similar across IMD 
quintiles. Among subjects identified as eligible to be controls, the refusal rate was similar 
across IMD quintiles, though slightly higher than in cases. (see Supplementary figure 1, 
available as supplementary data at IJE online) 
 
Cases were, more likely to be male, more likely to be in the most deprived IMD quintile, 
more likely to live in overcrowded households and had fewer educational qualifications than 
controls (Table 1). Cases were more likely to report regular travel to or a long-term stay (≥3 
months) in a high TB region. A higher proportion of cases than controls reported drinking at 
a hazardous or harmful level and reported being a smoker. The proportion of cases reporting 
having used class A drugs was twice as high as in controls. Similarly, a history of having 
ever been in prison or homeless was more frequent in cases than controls.  
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We were unable to trace NHS vaccination records for 96% of participants. For those traced 
with BCG vaccination recorded, 94% (34/36) either recalled BCG vaccination or had a BCG 
scar. For those traced and no BCG recorded, 71% had a BCG scar. Records were therefore 
not used. As there was a good level of agreement between self-reported history and scar 
inspection (86% agreement, kappa=0.6, p<0.001)17, information on self-reported history and 
scar examination were combined to classify the BCG status of participants, (as shown in 
Table 2). Controls were more likely to have had BCG vaccination than cases. 
 
Estimated effects of BCG vaccine on TB according to time since vaccination, for each 
model, are shown in Table 3. Area-level deprivation and education level met our retention 
criterion and were included in the partially adjusted model. In the fully adjusted model, we 
adjusted additionally for smoking, alcohol, use of controlled drugs, regular travel abroad to a 
high TB region, history of homelessness and history of prison stays. The remaining variables 
(long term travel abroad to a high TB region, average number of people per room, average 
number of people per bedroom) did not meet our retention criterion. 
 
In the complete case analyses, fewer than 1% of individuals were excluded because 
information was missing on BCG vaccination but a larger proportion were excluded because 
of missing information on confounding variables (17% in the fully adjusted model). The 
baseline model shows evidence of a moderate protective effect of BCG up to 25 years post 
vaccination (Table 3). This was attenuated in the partially adjusted model: the protective 
effect 20-25 years post vaccination was low. Results were similar, though with narrower 
confidence intervals, when the baseline and partially adjusted models included all subjects 
with complete data for those models (see Supplementary  Table 2, available as 
supplementary data at IJE online). Based on the fully adjusted model, there was good 
evidence of a protective effect of BCG 10 to 15 years (HR 0.49 95% CI 0.31,0.79) and 15 to 
20 years (HR 0.43 95% CI 0.28,0.67) since vaccination. The protective effect was lower after 
20 years: and 20 to 25 years (HR 0.75 95% CI 0.49,1.14)  and 25 to 29 years (0.99 95% CI 
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0.53,1.84) since vaccination. These estimates correspond to a VE of 51%, 57%, 25%, and 
1%, 10- 15, 15- 20, 20- 25 and 25- 29 years since vaccination, respectively  
 
The results based on multiple imputation of the missing data also indicated lower protection 
more than 20 years after BCG vaccination (Table 3).  Estimated VEs were 56%, 57%, 25% 
and 21%, 10-15, 15- 20, 20-25 and 25-29 years since vaccination. 
 
The association between BCG vaccination and log hazard of TB modelled using restricted 
cubic splines with 3 knots at 15, 20 and 25 years post-vaccination did not fit the data better 
than the linear model (based on the AIC). Results from analyses based on the simpler linear 
model suggested an estimated 7% (95% CI: 0.2% to 12%) increase in the log of the HR with 
each year from 10 years post-vaccination (Figure 1). The results using multiple imputation 
were similar to those from the complete case analysis, suggesting some protective effect of 
the vaccine up to about 25 years post-vaccination. The spline model suggested a fairly 
constant level of vaccine effectiveness up to around 17 years post vaccination, and then a 
steeper reduction in the VE after that (see Supplementary Figure 2, available as 
supplementary data at IJE online).  
 
Discussion  
Based on a large, population-based case-control study there was about a 50% protection 
against TB between 10 and 20 years following school-age BCG vaccination, with little 
evidence of good protection after 20 years. Although numbers were small there appeared to 
be subsequent waning in protection. Results from complete-case analyses and multiple 
imputation to deal with missing data were consistent.  
 
We had a moderately good response rate from cases and controls recruited to represent the 
children born in the UK in the general population. As we were able to locate few vaccination 
records we relied upon self-report of BCG vaccination and inspection of participants for BCG 
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scars to ascertain BCG vaccination status. The correspondence between the histories and 
the scar inspections was good.  There was some confounding in estimating the protective 
effect of BCG, due to lower BCG uptake in poorer subjects who had a higher risk of TB, but 
we were able to control for this in the analysis.  
 
A limitation in our approach was the inability to assess and exclude subjects who had a 
positive tuberculin skin test (TST) in the school vaccination programme, who would have 
been ineligible for vaccination.  Retrospective ascertainment of results of TST testing based 
on recall was not feasible, and participants’ recall could not be validated in the absence of 
records. Persons who have a positive response to a TST are known to be at higher risk of 
TB during the first few years after testing. However follow-up data from the British MRC BCG 
trial in adolescents showed that, in that low transmission setting, the risk of TB in participants 
with a positive TST test declined over time, and was similar to that of subjects who were TST 
negative at baseline by about 10 years after enrolment24, 25 (see figure 11 in ref17 for details ). 
Thus, not taking account of the TST results is unlikely to bias the association between BCG 
vaccination and TB beyond 10 years after vaccination. Also extrapolation from modelling 
work, 26  suggests that, in our study, the prevalence of tuberculin positivity in the white 
population would have been no greater than 4% at the time and age of screening for 
vaccination.  
 
Other limitations include the possibility that subjects taking part are more likely to have been 
vaccinated than those not contactable or who had refused. Cases were somewhat harder to 
contact than controls. Together with a higher response rate in cases than in controls, this 
might if anything, have acted to underestimate the protective effect of BCG. After 20 years a 
protective effect could no longer be detected after adjustment for confounding in the baseline 
model. Control for a wide range of confounders made little difference to the hazard ratio 10 
to 20 years after vaccination suggesting that if there were any other unmeasured 
confounders or residual confounding they may have limited effect. 
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This study provides evidence that adds to that from the original UK MRC trial, in which 
protection of 63% was reported 10 to 15 years after vaccination (with wide 95% confidence 
intervals, 17 to 84%). In that trial there was no evidence of protection 15 to 20 years after 
vaccination but the numbers of cases were small and the confidence interval consequently 
very wide (VE 9%, 95% CI <0 to 71%).24 The apparent waning of protection after 20 years 
has also been seen in Norway where moderately good protection was noted for 10-19 years 
after childhood BCG (VE 58% (CI 27%,76%), and lower protection 20-29 years  after 
vaccination (VE 38%, CI -32 to 71%).14.  In a Brazilian cohort protection in 15-20 year olds 
after infant BCG vaccination was 39% (9-58%), but with no data in older individuals.27  Other 
evidence for the duration of protection in high prevalence settings is limited. A  protective 
effect was noted in a case-control study in Saudi Arabian 15-24 year olds  after infant BCG 
vaccination (VE 67%, 95% CI 55-77%), but not in 25 to 34 year olds (VE 20%, CI -6 to 
37%).28   In contrast in an extended follow up of a BCG trial in US Native-Americans  
protection up to 60 years was reported.13  However it is unclear if such a long follow up might 
have acted to select those at lower risk of TB.  The above studies also do not indicate 
whether the protective effect of BCG in childhood is more durable, when it is assumed 
immune responses are better, than in infancy. 
 
It has been suggested that in high transmission settings and areas closer to the equator, 
masking of the effect of BCG occurs by infection or sensitisation by environmental 
mycobacteria increasingly providing, over time, some protection in the unvaccinated.5, 6, 29, 30  
The studies so far on durability of BCG have limited information with which to assess the role 
of masking.   
 
In summary, our case-control study suggests BCG vaccination in UK-born adolescents 
provided protection against tuberculosis for at least 20 years. BCG at school age may have 
helped in the control of TB, including reducing the risk of multidrug resistant disease as 
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those vaccinated around 13 years of age have been protected into adulthood. WHO’s End 
TB strategy notes the importance of continuing infant BCG vaccination in high prevalence 
settings.31, 32 We suggest also including a recommendation for childhood vaccination when 
infant vaccination has not been given. Our finding of longer duration of BCG protection may 
be helpful for countries assessing the cost-effectiveness of BCG in the prevention of 
tuberculosis. It also has implications for assessing new vaccines against tuberculosis,which 
should desirablyprovide protection which is greater than that from BCG and which might also 
be expected to provide lasting protection, although assessment of the latter would, in the 
short term, have to be based on immunological characteristics.   
 
Acknowledgements  
We thank the research team, interviewers, supervisors and the operation team members at 
NatCen as well as all the individuals who took part in the study. We also thank Lucy Trinder 
for help in data cleaning and management, colleagues from the TB Section, Public Health 
England, Child Health Information Services data managers, Immunisation co-ordinators  and 
our steering group team for support and advice. 
 
Contributors: LR and PM conceived the study. PM and PND supervised the fieldwork and 
data-management. PM, PND and LR provided academic leadership and other authors 
provided academic expertise and advice at key points. PND and RK carried out data 
cleaning and merging of data across sources. RK devised and carried out the analyses with 
assistance from PND. Additional expertise was provided in statistics and presentation of the 
results (JS); BCG epidemiology and study design (PF, PS); TB epidemiology in England, 
BCG vaccine records, and public health (IA, JW DE and ML), and estimating PPD positivity 
levels in the general population (EV). PM and PND wrote a first draft with RK.  All authors 
contributed to this paper.   
 
Page 15 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
16 
 
Funding: This work was supported by the National Institutes of Health Research Health 
technology Assessment (NIHR HTA) grant no 08/17/01. Other funding included a National 
Institute for Health Research (NIHR) Senior Investigator award NF-SI-0611-10168 (JS) 
NIHR Senior Investigator award NF-SI-0616-10037 (IA) and support from the MRC (IA, 
LR,PM), NIHR (IA,LR) BBSRC (PM) and PHE (IA).  
 
 
 
 
 
  
Page 16 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
17 
 
 
References 
1. World Health Organization. Global tuberculosis report 2016 2016 30th December 
2016. Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-
eng.pdf?ua=1. 
2. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin 
reaction in childhood and adolescence. Am J Epidemiol. 1974 Feb;99(2):131-8 
3. Public Health England. Tuberculosis in England 2016 (presenting data to end of 
2015)2016 [cited 2016. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/555343/TB_A
nnual_Report_2016_GTW2309.pdf. 
4. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in 
tuberculosis vaccine development and host-directed therapies--a state of the art review. The 
Lancet Respiratory medicine. 2014 Apr;2(4):301-20 
5. Fine PEM. Variation in protection by BCG: Implications of and for heterologous 
immunity. Lancet. 1995;346(8986):1339-45 
6. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by 
BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society of 
America. 2014 Feb;58(4):470-80 
7. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect 
of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic 
review and meta-analysis. BMJ. 2014;349:g4643 
8. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of 
tuberculosis in adolescence and early adult life. Final report to the Medical Research Council 
5535. British Medical Journal. 1977;2(6082):293-5 
9. Sutherland I. Effectiveness of BCG vaccination in England and Wales in 1983. 
Tubercle. 1987;68(2):81-92 
Page 17 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
18 
 
10. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time 
since vaccination? Int J Tuberc Lung Dis. 1998;2(3):200-7 
11. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al. Systematic 
review and meta-analysis of the current evidence on the duration of protection by bacillus 
Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013 
Sep;17(37):1-372 
12. Barreto ML, Cunha SS, Pereira SM, Genser B, Hijjar MA, Ichihara MY, et al. 
Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil 1251. International 
journal of tuberculosis and lung disease. 2005;9(10):1171-3 
13. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, 
et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year 
follow-up study. JAMA : the journal of the American Medical Association. 2004 May 
5;291(17):2086-91 
14. Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P. Duration of 
BCG protection against tuberculosis and change in effectiveness with time since vaccination 
in Norway: a retrospective population-based cohort study. Lancet Infect Dis. 2016 
Feb;16(2):219-26 
15. Gorak-Stolinska P, Weir RE, Floyd S, Lalor MK, Stenson S, Branson K, et al. 
Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 
1077 BCG vaccine. Vaccine. 2006 Jul 17;24(29-30):5726-33 
16. Office TNA. Procurement of Vaccines by the Department of Health2003 12th October 
2016 [30 p.]. Available from: https://www.nao.org.uk/wp-
content/uploads/2003/04/0203625.pdf. 
17. Mangtani PN-D, P; Keogh,R; Trinder,L; Smith,P;Sterne,J; Abubakar,I; Vynnycky,E; 
Watson,J; Elliman,D; Lipman,M; Rodrigues,LC. NIHR/HTA study 08/17/01: Observational 
study to estimate the changes in the effectiveness of bcg with the time since vaccination for 
preventing tuberculosis in the uk. Health Technol Assess. 2017 [In Press] 
Page 18 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
19 
 
18. Office for National Statistics. The English Indices of Deprivation 2010 2011. Available 
from: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010. 
19. Keogh RH, Cox DR. Case-subcohort studies.  Case-control studies: Cambridge 
University Press; 2014. p. 191-211. 
20. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease 
prevention trials. Biometrika. 1986;73(1):1-11 
21. Keogh RH, Mangtani P, Rodrigues L, Nguipdop Djomo P. Estimating time-varying 
exposure-outcome associations using case-control data: logistic and case-cohort analyses. 
BMC Med Res Methodol. 2016;16:2 
22. Information Theory and an Extension of the Maximum Likelihood Principle. Second 
International Symposium on Information Theory. Akaike H, editor. Budapest Akademiai 
Kiado; 1973. 
23. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. 
BMJ. 2009;338:b2393 
24. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of 
tuberculosis in adolescence and early adult life. Final report to the Medical Research 
Council. British Medical Journal. 1977;2(6082):293-5 
25. Fourth report to the Medical Research Council by its Tuberculosis Vaccines Clinical 
Trials Committee. BCG and vole bacillus vaccines in the prevention of tuberculosis in 
adolescence and early adult life. Bulletin of the World Health Organization. 1972;1972. 46:3-
85 
26. Vynnycky E, Fine PE. The annual risk of infection with Mycobacterium tuberculosis in 
England and Wales since 1901. Int J Tuberc Lung Dis. 1997 Oct;1(5):389-96 
27. Barreto ML, Cunha SS, Pereira SM, Genser B, Hijjar MA, Yury Ichihara M, et al. 
Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung 
Dis. 2005 Oct;9(10):1171-3 
Page 19 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
20 
 
28. Al Kassimi FA, Al Hajjaj MS, Al Orainey IO, Bamgboye EA. Does the protective effect 
of neonatal BCG correlate with vaccine-induced tuberculin reaction? 639. American Journal 
of Respiratory and Critical Care Medicine. 1995;152(5 I):1575-8 
29. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG 
vaccination and tuberculosis. AmRevRespirDis. 1966;94(4):553-68 
30. Valadas E. Nontuberculous mycobacteria: clinical importance and relevance to 
bacille Calmette-Guerin vaccination. ClinInfectDis. 2004;39(4):457-8 
31. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new 
end TB strategy. Lancet. 2015 May 2;385(9979):1799-801 
32. Organization WH. Documentation for World Health Assembly 67 Geneva: WHO; 
2014 [02.04.2017]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_11-
en.pdf  
33. Rehm J, Greenfield TK, Walsh G, Xie X, Robson L, Single E. Assessment methods 
for alcohol consumption, prevalence of high risk drinking and harm: a sensitivity analysis. Int 
J Epidemiol. 1999 Apr;28(2):219-24 
 
 
 
Page 20 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
21 
 
Table 1 Characteristics of study participants by case and control status 
Characteristic Cases Controls 
 (n=677) % (n=1170) % 
Birth Cohort 
1965-1969 65 9.6 174 14.9 
1970-1974 178 26.3 312 26.7 
1975-1979 215 31.8 260 22.2 
1980-1989 219 32.4 424 36.2 
Sex 
Female 341 50.4 700 59.8 
Male 336 49.6 470 40.2 
Quintiles of LSOA-level Index of Multiple Deprivation 
1 (least deprived) 63 9.3 234 20.0 
2 99 14.6 234 20.0 
3 109 16.1 234 20.0 
4 130 19.2 234 20.0 
5 (most deprived) 276 40.8 234 20.0 
Highest educational (academic, professional and or vocational)  qualification 
None 132 19.5 75 6.4 
O Levels or equivalenta 207 30.6 363 31.0 
A Levels or equivalentb 91 13.4 246 21.0 
Degree level or equivalentc 216 31.9 455 38.9 
Missing 31 4.6 31 2.7 
Average number of people per room 
Less than or equal to 1 634 93.7 1144 97.8 
Greater than 1 26 3.8 24 2.1 
Missing 17 2.5 2 0.2 
Average number of people per bedroom 
Less than or equal to 1 385 56.9 705 60.3 
Greater than 1 275 40.6 463 39.6 
Missing 17 2.5 2 0.2 
TB infection risk from regular travels abroad 
Lowd 618 91.3 1099 93.9 
Highe 58 8.6 71 6.1 
Missing 1 0.2 0 0.0 
TB infection risk from long-term (≥ 3 months) stays abroad 
Lowd 607 89.7 1113 95.1 
Highe 70 10.3 57 4.9 
Alcohol drinking
f
 
Very low/no risk 166 24.5 329 28.1 
Low risk 346 51.1 632 54.0 
Hazardous risk 36 5.3 68 5.8 
Harmful risk 41 6.1 25 2.1 
Missing 88 13.0 116 9.9 
Tobacco smoking 
Never smoker 188 27.8 499 42.7 
Ex-smoker 62 9.2 135 11.5 
Smoker: <20 pack-years 308 45.5 422 36.1 
Smoker: >=20 pack-years 99 14.6 85 7.3 
Missing 20 3.0 29 2.5 
Drug misuse/abuse
g
 
No drug use 379 56.0 847 72.4 
Class B and/or C use only 69 10.2 108 9.2 
Class A use  217 32.1 188 16.1 
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Missing 12 1.8 27 2.3 
History of homelessness     
Never been homeless for >1 week 553 81.7 1091 93.2 
Ever been homeless for >1 week 117 17.3 68 5.8 
Missing 7 1.0 11 0.9 
History of prison stay
h
     
Never detained 590 87.2 1119 95.6 
Ever detained in the UK or abroad 82 12.1 35 3.0 
Missing 5 0.7 16 1.4 
a1
O Levels, GCEs, or GCSEs (any grades), City & Guilds Craft/Ordinary Level or NVQ Level 1 or 2 
b 
A Levels, SCE Higher, ONC/ONT/BEC/TEC, City & Guilds Advanced Final Level or NVQ Level 3 
c
Degree Level, Teaching qualification, HNC/HND, BEC/TEC Higher or BTEC Higher 
d
Regular travel (i.e. every few years or more often) or long-term (>3 months) stay to Eastern Europe, Caribbean, 
or none of the places specified 
e
Regular travel (i.e. every few years or more often) or long-term (≥3 months) stays to Africa or Asia 
f
Alcohol drinking based on combination on drinking frequency and quantity in UK standard units, and cut-offs by 
gender as proposed by Rehm et al
33
. Cut-offs for hazardous and harmful drinking respectively (20g/day and 
40g/day) in women and (40g/day and 60g/day) in men. Subjects who stopped drinking 5 years or more ago 
classified as low risk.   
g
Class B and C examples included benzodiazepines, cannabis, qat, glue, gas, solvents, and amphetamines. 
Class A drug examples included ecstasy, cocaine, crack, heroin, LSD, magic mushrooms 
h
72/82 (88%) cases and 33/35 (94%) controls with history of prison stay report only ever been in prison in the UK 
and not abroad.   
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Table 2: BCG vaccination status based on a combination of self-report and scar reading, among 677 cases and 1170 controls 
Self-reported history 
Scar 
inspection 
Cases 
 
Controls 
 
Assigned vaccination status Cases Controls 
  (n=677) (n=1170)    
Convincinga BCG Present 391 (57.8%) 776 (66.3%) 
“Vaccinated” 473 (69.9%) 933 (79.7%) 
Convincing BCG  None 57 (8.4%) 117 (10%) 
Convincing BCG NI 22 (3.2%) 29 (2.5%) 
Probablea BCG  Present 3 (0.4%) 11 (0.9%) 
Probable BCG history None 3 (0.4%) 18 (1.5%) 
“Likely vaccinated”b 33 (4.9%) 78 (6.7%) 
Probable BCG history NI 0 (0%) 3 (0.3%) 
No BCG history Present 16 (2.4%) 27 (2.3%) 
Unsure Present 14 (2.1%) 30 (2.6%) 
No BCG history None 135 (19.9%) 122 (13.4%) 
“Not vaccinated” 163 (24.1%) 154 (13.2%) No BCG history NI 19 (2.8%) 20 (1.7%) 
Unsure None 9 (1.3%) 12 (1.0%) 
Unsure NI 8 (1.2%) 5 (0.4%) Missing 8 (1.2%) 5 (0.4%) 
 
NI: not inspected 
a
If there was recall of being given BCG at school and either a clear recall of a prior tuberculin skin test (TST) test or a pustule or scarring post vaccination, this was categorised 
as a convincing history, if only recall of BCG at school it was categorised as probable. 
b
sensitivity analysis moving this category to the vaccinated did not change the effect estimate of the association between BCG and TB and had small numbers, they were 
therefore assigned to the vaccinated category in the rest of the results  
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Table 3. Results from complete case analyses (based on the 532 cases and 993 controls used in the fully adjusted model) and from 
analyses of 677 cases and 1170 controls based on multiple imputation 
 Baseline modela Partially adjusted model b Fully adjusted modelc 
 HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Complete case analyses      
Unvaccinated 1 (ref)  1 (ref)  1 (ref)  
Vaccinated 10-15 years ago 0.43 (0.28,0.66) <0.001 0.49 (0.31,0.79) 0.004 0.49 (0.31,0.79) 0.003 
Vaccinated 15-20 years ago 0.34 (0.23,0.50) <0.001 0.41 (0.27,0.63) <0.001 0.43 (0.28,0.67) <0.001 
Vaccinated 20-25 years ago 0.56 (0.39,0.80) 0.001 0.69 (0.46,1.02) 0.065 0.75 (0.49,1.14) 0.174 
Vaccinated 25-29 years ago 0.70 (0.40,1.24) 0.225 0.88 (0.48,1.59) 0.660 0.99 (0.53,1.84) 0.970 
Analyses based on multiple imputation     
 
Unvaccinated   1 (ref)  1 (ref)  
Vaccinated 10-15 years ago   0.43 (0.29,0.67) <0.001 0.44 (0.28,0.67) <0.001 
Vaccinated 15-20 years ago   0.42 (0.29,0.62) <0.001 0.43 (0.29,0.64) <0.001 
Vaccinated 20-25 years ago   0.70 (0.49,1.00) 0.049 0.75 (0.52,1.10) 0.141 
Vaccinated 25-29 years ago   0.71 (0.42,1.19) 0.195 0.79 (0.45,1.39) 0.406 
a
The baseline model is stratified on birth cohort and adjusted for sex 
b
The partially adjusted model is additionally adjusted for confounding variables area-level deprivation and 
educational level. 
c
The fully adjusted model has additional adjustment for lifestyle confounding variables (tobacco smoking, alcohol drinking and misuse/abuse of controlled 
drugs), history of homelessness, history of prison stays, TB infection risk from regular travels abroad.
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Figure 1: Results from modelling the time-varying effect of the vaccine as a linear 
function of time (on a log scale) 
 
 
 
 
 
 
 
Legend figure 1 
The left-hand vertical axis shows the vaccine effectiveness (VE) and the right-hand vertical axis 
shows the hazard ratio (HR) , both on the log scale. Results are based on the fully adjusted model. 
The dashed lines show the 95% confidence bounds 
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